市場調查報告書
商品編碼
1395976
數位治療 - 主題智能Digital Therapeutics - Thematic Intelligence |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
數位治療 (DTx) 是更廣泛的數位健康領域解決方案的一個分支,為疾病的預防、治療和管理提供實證治療介入。 DTx 產品經過不同程度的臨床評估和監管監督,由軟體程式提供支持,並在從智慧型手機到虛擬實境 (VR) 耳機等各種設備上提供。 DTx 可能是以患者為中心的醫療保健的未來,隨時隨地為患者提供個人化方案,甚至可以消除某些適應症的藥物需求。
數位治療 (DTx) 是更廣泛的數位健康領域解決方案的一個分支,為疾病的預防、治療和管理提供實證治療介入。 DTx 產品經過不同程度的臨床評估和監管監督,由軟體程式提供支持,並在從智慧型手機到虛擬實境 (VR) 耳機等各種設備上提供。 DTx 可能是以患者為中心的醫療保健的未來,隨時隨地為患者提供個人化方案,甚至可以消除某些適應症的藥物需求。
醫療保健當局和付款人對 DTx 的價值普遍存在不確定性,這阻礙了市場的發展。 漫長的流程和不明確的要求使得報銷變得困難並限制了患者的使用。 救贖重要性最明顯的例子就是 Pear Therapeutics 的破產。 該公司2021年的估值預計為16億美元,但2023年拍賣總價降至600萬美元。 這是因為 Pear Therapeutics 面臨市場波動和研發成本高昂的困擾,同時也未能為其產品獲得足夠的報銷。 該公司的破產證明,監管只是 DTx 製造商面臨的第一個挑戰,如果不做出改變,其他參與者可能很快就會破產。
全球醫療保健當局正在努力解決 DTx 等數位醫療技術缺乏監管和報銷途徑的問題。 德國、比利時和法國的醫療當局已經建立了框架,包括韓國在內的其他國家的當局正在尋求效仿。 在美國,透過醫療補助和醫療保險報銷的進展可能會根據新立法的成功或失敗而有所改善,而在英國,與英國脫歐相關的監管變化可能會導致批准範圍擴大。 儘管監管格局目前較為分散,但加強數位醫療監管標準的國際合作可能會在未來改善患者獲得更安全、更有效的 DTx 的機會。
本報告審視了全球數位治療市場,匯集了有關醫療保健、宏觀經濟、技術和監管趨勢將如何影響數位治療市場的最新見解和預測。,還提供了對整個價值領域的主要進入者和未來顛覆者的見解。鏈。
Digital therapeutics (DTx) is a segment of solutions within the wider digital health landscape that delivers evidence-based therapeutic interventions to prevent, treat, or manage disease. Subject to different degrees of clinical evaluation and regulatory oversight, DTx products are driven by software programs and delivered across a range of devices from smartphones to virtual reality (VR) headsets. DTx could be the future of patient-centric healthcare, able to provide personalized programs to patients anywhere and at any time, even removing the need for medications for some indications.
DTx provides many benefits to both patients and providers
Digital therapeutics (DTx) is a segment of solutions within the wider digital health landscape that delivers evidence-based therapeutic interventions to prevent, treat, or manage disease. Subject to different degrees of clinical evaluation and regulatory oversight, DTx products are driven by software programs and delivered across a range of devices from smartphones to virtual reality (VR) headsets. DTx could be the future of patient-centric healthcare, able to provide personalized programs to patients anywhere and at any time, even removing the need for medications for some indications.
Reimbursement is crucial for the widespread adoption of DTx
There is widespread uncertainty from both healthcare authorities and payors about the value of DTx, which is staunching the market. Lengthy processes and unclear requirements have made reimbursement difficult to navigate, limiting patient access. The most prominent example of the importance of reimbursement is the bankruptcy of Pear Therapeutics. The company was estimated to be worth of $1.6 billion in 2021, then fell to a total auction price of $6 million in 2023 as Pear Therapeutics failed to generate sufficient reimbursement for its products while also struggling with unstable market conditions and high R&D costs. The company's bankruptcy proves that regulation is only the first challenge for DTx manufacturers, and without change, other players may also fail soon.
Evolving regulatory and reimbursement pathways
Healthcare authorities worldwide are addressing the lack of regulatory and reimbursement pathways for digital health technologies such as DTx. Health authorities in Germany, Belgium, and France have established frameworks, that those in other countries, such as South Korea, are trying to emulate. In the US, progress in reimbursement through Medicaid and Medicare may improve depending on the success of newly introduced bills, while changing regulations in the UK following Brexit could lead to increased approvals. Although the regulatory landscape is currently divided, increasing international cooperation on the regulatory standards of digital health would improve patient access to safer and more effective DTx in the future.
This report consolidates GlobalData's latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the digital therapeutics market, as well as providing insights into the leading players and future disruptors across the value chain.
The report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for digital therapeutics.